Literature DB >> 8864963

Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a].

C Edelstein1, J A Italia, O Klezovitch, A M Scanu.   

Abstract

We have previously shown that a functional free apolipoprotein[a] (apo[a]) can be isolated from its parent lipoprotein[a] (Lp[a]) by a mild reductive procedure. To shed further light on the properties of Lp[a] and apo[a] we subjected them to a limited proteolysis by porcine pancreatic elastase. This enzyme cleaved both at the Ile3520-Leu3521 bond in the linker between kringles IV-4 and IV-5 of apo[a] generating two fragments F1 and F2. In contrast to F1, which represented the N-terminal portion of apo[a] and was functionally inert, F2, representing the C-terminal domain, bound to lysine-Sepharose, fibrinogen, and fibronectin and formed a miniLp[a] particle when incubated with LDL. The proteolytic pattern by pancreatic elastase was also exhibited by human leukocyte elastase. F1, injected intravenously into normal mice, was rapidly cleared (Ty2, 2.9 h) and after 1 h fragments in the size range of 100-33 kDa were observed in the urine. In turn, F2 had a longer residence time (Ty2, 5 h) and was excreted in the urine only after 5 h as fragments of 70-45 kDa. Fragments in the same size range as found after F1 injection were also present in the urine after injection of apo[a] or Lp[a]. Moreover, apo[a] fragments of the size seen in mouse urine were spontaneously present in normal human urine and appeared derived from larger apo[a] fragments in the plasma. Our results indicate that enzymes of the elastase family cleave human apo[a] in vitro into two main fragments that differ in structural and functional properties and metabolic behavior. The comparable size of apo[a] fragments observed in the urine of humans and injected mice invites the speculation that enzymes of the elastase family may play a role in the biology of Lp[a] in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864963

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

Review 1.  Lipoprotein(a) and coronary heart disease risk.

Authors:  S M Marcovina; R A Hegele; M L Koschinsky
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

Review 2.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

3.  Successful utilization of lyophilized lipoprotein(a) as a biological reagent.

Authors:  Angelo M Scanu; Janet Hinman; Ditta Pfaffinger; Celina Edelstein
Journal:  Lipids       Date:  2004-06       Impact factor: 1.880

4.  A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response.

Authors:  Jane Hoover-Plow; Erika Hart; Yanqing Gong; Aleksey Shchurin; Tracey Schneeman
Journal:  Exp Biol Med (Maywood)       Date:  2008-11-07

Review 5.  Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications.

Authors:  Angelo M Scanu
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

6.  Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.

Authors:  Angelo M Scanu; Janet Hinman
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

7.  The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin.

Authors:  Celina Edelstein; Binu Philips; Ditta Pfaffinger; Angelo M Scanu
Journal:  FASEB J       Date:  2008-11-10       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.